Beyondspring Pharmaceuticals Inc., of New York, which is developing an immuno-oncology agent plinabulin, in a phase III trial for the reduction of docetaxel-induced neutropenia, has amended its IPO filing to now raise up to $3 million by offering 143,000 shares in the price range of $20 to $22.